Acute vincristine pretreatment protects adult mouse cardiac myocytes from oxidative stress

被引:17
作者
Chatterjee, Kanu
Zhang, Jianqing
Honbo, Norman
Simonis, Uschi
Shaw, Robin
Karliner, Joel S.
机构
[1] Univ Calif San Francisco, Div Cardiol, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA
[4] Univ Calif San Francisco, Chatterjee Ctr Cardiac Res, San Francisco, CA 94143 USA
[5] San Francisco State Univ, Dept Chem & Biochem, San Francisco, CA USA
关键词
vincristine; cardiac myocytes; cell culture; hydrogen peroxide; oxidative stress; hypoxia; cardioprotection; signal transduction;
D O I
10.1016/j.yjmcc.2007.06.005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Vincristine is a chemotherapeutic agent that disrupts microtubules. We noted that paclitaxel (Taxol), which stabilizes microtubules, protected cultured adult mouse cardiac myocytes from oxidative stress induced by H2O2. We hypothesized that vincristine, which disrupts microtubules, should have the opposite effect. To our surprise, we found that pretreatment with concentrations of vincristine ranging from 30 to 120 mu mol/L for 60 min preserved myocyte viability and morphology after incubation with 30 mu mol/L of H2O2 for 35 min as measured by trypan blue exclusion. The cardioprotective effects of vincristine were also observed during prolonged hypoxia. With continuous exposure to vincristine, survival lasted for as long as 24 h, but longer periods of exposure up to 42 h resulted in extensive cell death. Despite microtubule disruption evidenced on deconvolution microscopy, vincristine activated a prosurvival pathway resulting in increased phosphorylation of Akt, ERK and GSK-3 and in reduced cytochrome C release into the cytosol. Pharmacological inhibitors of Akt and Erk attenuated the cardioprotective effect of vincristine. We conclude that short-term pretreatment with vincristine exerts dramatic protective effects in cultured adult mouse myocytes subjected to acute oxidative stress. Despite causing microtubule disruption, vincristine initiates a prosurvival signaling pathway. As vincristine and doxorubicin are often used in conjunction to treat patients, it is possible that vincristine could be used to modify the cardiotoxicity of doxorubicin. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:327 / 336
页数:10
相关论文
共 32 条
[1]  
[Anonymous], 1990, ALKALOIDS
[2]   EFFECTS OF 2,3-BUTANEDIONE MONOXIME (BDM) ON CONTRACTURE AND INJURY OF ISOLATED RAT MYOCYTES FOLLOWING METABOLIC INHIBITION AND ISCHEMIA [J].
ARMSTRONG, SC ;
GANOTE, CE .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 1991, 23 (09) :1001-1014
[3]   Inhibition of mitochondrial permeability transition prevents mitochondrial dysfunction, cytochrome c release and apoptosis induced by heart ischemia [J].
Borutaite, V ;
Jekabsone, A ;
Morkuniene, R ;
Brown, GC .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2003, 35 (04) :357-366
[4]  
Chu E., 2004, BASIC CLIN PHARMACOL, V9th, P898
[5]   A selective ε-protein kinase C antagonist inhibits protection of cardiac myocytes from hypoxia-induced cell death [J].
Gray, MO ;
Karliner, JS ;
Mochly-Rosen, D .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (49) :30945-30951
[6]   Overexpression of the rat sarcoplasmic reticulum Ca2+ ATPase gene in the heart of transgenic mice accelerates calcium transients and cardiac relaxation [J].
He, HP ;
Giordano, FJ ;
HilalDandan, R ;
Choi, DJ ;
Rockman, HA ;
McDonough, PM ;
Bluhm, WF ;
Meyer, M ;
Sayen, MR ;
Swanson, E ;
Dillmann, WH .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (02) :380-389
[7]   Characterization of G-protein signaling in ventricular myocytes from the adult mouse heart: Differences from the rat [J].
Hilal-Dandan, R ;
Kanter, JR ;
Brunton, LL .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2000, 32 (07) :1211-1221
[8]  
Huang Y, 2004, MOL CANCER THER, V3, P271
[9]   Role of Ced3/ICE-family proteases in staurosporine-induced programmed cell death [J].
Jacobson, MD ;
Weil, M ;
Raff, MC .
JOURNAL OF CELL BIOLOGY, 1996, 133 (05) :1041-1051
[10]  
Jordan M. A., 2002, Current Medicinal Chemistry - Anti-Cancer Agents, V2, P1, DOI 10.2174/1568011023354290